Age-related characteristics of gastric carcinoma in young and elderly patients

Cancer

Volumn 77, Issue 9, 1996, Pages 1774-1780

  Maehara, Yoshihiko ^a,b   Emi, Yasunori ^a   Tomisaki, Shinichi ^a   Oshiro, Tatsuo ^a   Kakeji, Yoshihiro ^a   Ichiyoshi, Yuji ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

gastric cancer; geriatric; p53; prognosis; proliferating cell nuclear antigen; younger patients

Indexed keywords

CYCLINE; PROTEIN P53;

ADULT; AGED; AGING; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; EARLY DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AGING; CARCINOMA; CELL DIVISION; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LIVER NEOPLASMS; LYMPH NODE EXCISION; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0029866051     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1774::AID-CNCR3>3.0.CO;2-C     Document Type: Article

References (51)

1. Maehara Y, Sakaguchi Y, Moriguchi S, Orita H, Korenaga D, Kohnoe S, et al. Signet ring cell carcinoma of the stomach. Cancer 1992;69:1645-50.
2. Bittner R, Schirrow H, Butters M, Roscher R, Krautzberger W, Oettinger W, et al. Total gastrectomy. A 15-year experience with particular reference to the patient over 70 years of age. Arch Surg 1985;120:1120-5.
3. Coluccia C, Ricci EB, Marzola GG, Molaschi M, Nano MG. Gastric cancer in the elderly: results of surgical treatment. Int Surg 1987;72:4-10.
4. Tso PL, Bringaze III WL, Dauterive AH, Correa P, Cohn I. Gastric carcinoma in the young. Cancer 1987;59:1362-5.
5. Matley PJ, Dent DM, Madden MV, Price S. Gastric carcinoma in young adults. Ann Surg 1988;208:593-6.
6. Maehara Y, Orita H, Moriguchi S, Emi Y, Haraguchi M, Sugimachi K. Lower survival rate for patients under 30 years of age and surgically treated for gastric carcinoma. Br J Cancer 1991;63:1015-7.
7. Maehara Y, Oshiro T, Oiwa H, Oda S, Baba H, Akazawa K, et al. Gastric cancer in patients over 70 years of age. Br J Surg 1995;82:102-5.
8. Zhang Z-F, Apriklan A, Sarkis AS, Zeng Z-S, Pollack D, Cordon-Cardo C, et al. Factors associated with p53 nuclear accumulation in prostate adenocarcinoma. Int J Oncol 1994;4:897-902.
9. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6.
10. Kashii T, Mizushima Y, Lima CEQ, Noto H, Sato H, Saito H, et al. Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene alterations: Comparison between younger and older groups. Oncology 1995;52:219-15.
11. Landberg G, Tan EM, Roos G. Flowcytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: A new view of the cell cycle. Exp Cell Res 1990;187:111-8.
12. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989;134:733-9.
13. Kawasaki S. A clinicopathological study on upward intramural extension of cancer of the stomach (in Japanese with English Abstract). Fukuoka Acta Medica 1975;66:1-3.
14. Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persano S, Andreola S, et al. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 1982;196:685-90.
15. Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D, et al. Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time. Cancer 1992;70:392-5.
16. Korenaga D, Okamura T, Baba H, Saito A, Sugimachi K. Results of resection of gastric cancer extending to adjacent organs. Br J Surg 1988;75:12-5.
17. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology and Histological Classification of gastric cancer. Part I and II. Clinical Classification. Jpn J Surg 1981;11:127-145.
18. Japanese Research Society for Gastric Cancer. The General Rules for Gastric Cancer Study (in Japanese). 12th ed. Tokyo: Kanehara and Company, 1993.
19. Lauwers GY, Wahl SJ, Melamed J, Rojas-Corona RR. p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. Am J Gastroenterol 1993;88:1916-9.
20. Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454-9.
21. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993;67:589-93.
22. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
23. Maehara Y, Oshiro T, Baba H, Ohno S, Kohnoe S, Sugimachi K. Lymphatic invasion and potential for tumor growth and metastasis in patients with gastric cancer. Surgery 1995; 117:380-5.
24. Dixon WJ, editor. BMDP Statistical Software. Berkeley: University of California Press, 1988.
25. Fujimoto S, Takahashi M, Ohkubo H, Mutou T, Kure M, Masaoka H, et al. Comparative clinicopathologic features of early gastric cancer in young and older patients. Surgery 1994;115:516-20.
26. Mitsudomi T, Watanabe A, Matsusaka T, Fujinaga Y, Fuchigami T, Iwashita A. A clinicopathological study of synchronous multiple gastric cancer. Br J Surg 1989;76:237-40.
27. Korenaga D, Orita H, Okuyama T, Moriguchi S, Maehara Y, Sugimachi K. Quality of life after gastrectomy in patients with carcinoma of the stomach. Br J Surg 1992;79:248-50.
28. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination and liver metastasis. Surgery 1991;110:820-3.
29. Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992;1:341-6.
30. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res 1990;50:3952-5.
31. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-6.
32. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
33. Maehara Y, Okuyama T, Kakeji Y, Endo K, Yamamoto M, Sugimachi K. A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. Br J Cancer 1995;71:999-1002.
34. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-11.
35. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
36. Gannon JP, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-1602.
37. Lee S-H, Hurwitz J. Mechanism of elongation of primed DNA by DNA polymerase δ, proliferating cell nuclear antigen, and activator 1. Proc Natl Acad Sci USA 1990;87:5672-6.
38. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990;96:121-9.
39. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
40. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
41. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
42. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-6.
43. Kakeji Y, Maehara Y, Adachi Y, Baba H, Mori M, Furusawa M, et al. Proliferating activity as a prognostic factor in Borrmann type 4 gastric carcinoma. Br J Cancer 1994;69:749-53.
44. Maeda K, Chung Y-S, Onoda N, Kato Y, Nitta A, Arimoto Y, et al. Proliferating cell nuclear antigen labeling index of preoperative biopsy specimens in gastric carcinoma with special reference to prognosis. Cancer 1994;73:528-33.
45. Balducci L, Phillips M, Wallace C, Hardy C. Cancer chemotherapy in the elderly. Am Fam Physician 1987;35:133-43.
46. Schwab R, Walters CS, Weksler ME. Host defence mechanisms and aging. Semin Oncol 1989;16:20-7.
47. Maehara Y, Takahashi I, Yoshida M, Baba H, Kusumoto H, Anai H, et al. Postgastrectomy anticancer chemotherapy for stage IV gastric cancer equally tolerable for patients under and over age 65. Anticancer Res 1993;13:27-30.
48. Kusumoto H, Maehara Y, Kusumoto T, Anai H, Akazawa K, Sugimachi K. Chemosensitivity differences between primary and metastatic liver cancers. Eur J Surg Oncol 1988;14:685-9.
49. Kaibara N, Okamoto T, Kimura O, Iitsuka Y, Takebayashi M, Yurugi E, et al. Possible role of lymph node dissection in the surgical treatment of gastric cancer with disseminating peritoneal metastasis. Jpn J Surg 1983;13:404-8.
50. Kano T, Kawami H, Hohdono S, Oka N, Inokuchi K. Intraoperative intraperitoneal administration of CDDP against gastric cancer with peritoneal dissemination. Jpn J Cancer Chemother 1990;17:233-7.
51. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K. Postoperative immunochemotherapy including Streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 1994;168:36-40.